K. Venuprasad, Chris Elly, Min Gao, Shahram Salek-Ardakani, Yohsuke Harada, Jun-Li Luo, Chun Yang, Michael Croft, Kazushi Inoue, Michael Karin, Yun-Cai Liu
J Clin Invest. 2006;
116(4):1117
doi:10.1172/JCI26858
Abstract |
Full text
|
PDF
|
Supplemental material
T
he immune system is capable of mounting robust responses against invading pathogens but refrains from attacking self. Many studies have focused on tolerance induction of Th1 cells, whose failure results in development of autoimmune diseases. However, the molecular mechanisms governing tolerance induction in Th2 cells and its relation to allergic responses remain unclear. Here we used both in vivo and in vitro protocols to demonstrate that Th2 cells either containing a mitogen and extracellular kinase kinase 1 (MEKK1) mutant or lacking JNK1 or the E3 ubiquitin ligase Itch cannot be tolerized. In a mouse allergic model, injection of high-dose tolerizing antigen failed to block the development of airway inflammation in Itch–/– mice. This study suggests that MEKK1-JNK signaling regulates Itch E3 ligase–mediated tolerogenic process in Th2 cells. These findings have therapeutic implications for allergic diseases.
